Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ifenprodil tartrate 是典型的非竞争性 NMDA 受体拮抗剂,抑制 GIRK (Kir3),通过基底 GIRK 活性减少内向电流,有用做脑血管舒张试剂的潜力。它对 NR1A/NR2B 受体亲和力是 NR1A/NR2A 受体的 400 倍。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 197 | 现货 | ||
25 mg | ¥ 355 | 现货 | ||
50 mg | ¥ 587 | 现货 | ||
100 mg | ¥ 990 | 现货 | ||
500 mg | ¥ 2,150 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 646 | 现货 |
产品描述 | Ifenprodil is a selective NMDA receptor (glutamate) antagonist. |
靶点活性 | NMDAR:0.3 μM |
体内活性 | Ifenprodil抑制NMDA(10 μM)和NMDA(100 μM)诱发的电流,IC 50值分别为0.88 μM和0.17μ。在大鼠皮质神经元中,Ifenprodil(10 μM)抑制大部分的NMDA受体诱发的电流。 |
激酶实验 | In vitro biochemical and pharmacological assaysinhibition studies with recombinant human COX-1 and COX-2: Microsomal preparations of recombinant human COX-1 and COX-2 are prepared from a vaccinia virus-COS-7 cell expression system. Recombinant human COX-1 and COX-2 are expressed in baculovirus-Sf9 cells, and enzymes are purified. Enzymatic activity is monitored continuously by either a fluorescence assay measuring the appearance of the oxidized form of the reducing agent cosubstrate homovanillic acid or by oxygen consumption. The HPLC assay for the assessment of inhibition of purified COX-1 by Rofecoxib with 0.1 μM arachidonic acid substrate concentration, the determination of the stoichiometry of the complex between COX-2 and Rofecoxib, the dissociation rate constant of the enzyme-inhibitor complex by recovery of enzymatic activity, and the recovery of intact Rofecoxib from that complex are all performed as described previously. The solvent system for the HPLC analysis of Rofecoxib is 15:85 MeOH/aqueous potassium phosphate (1 g/liter), with elution by a linear gradient of 15 to 75% MeOH over 25 minutes with detection at 275 nm on a Novapak C18 column. |
分子量 | 400.49 |
分子式 | C21H27NO2·1/2C4H6O6 |
CAS No. | 23210-58-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 88 mg/mL (163.4 mM)
Ethanol: 58 mg/mL (107.7 mM)
H2O: 9 mg/mL (11.23 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol / H2O | 1 mM | 2.4969 mL | 12.4847 mL | 24.9694 mL | 62.4235 mL |
5 mM | 0.4994 mL | 2.4969 mL | 4.9939 mL | 12.4847 mL | |
10 mM | 0.2497 mL | 1.2485 mL | 2.4969 mL | 6.2424 mL | |
DMSO / Ethanol | 20 mM | 0.1248 mL | 0.6242 mL | 1.2485 mL | 3.1212 mL |
50 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2485 mL | |
100 mM | 0.025 mL | 0.1248 mL | 0.2497 mL | 0.6242 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ifenprodil Tartrate 23210-58-4 Membrane transporter/Ion channel Neuroscience Potassium Channel NMDAR iGluR KcsA inhibit vasodilator current Ionotropic glutamate receptors Ifenprodil NR1A Inhibitor NMDA cerebral NR2B inhibitor